skip to main content
Give

Jayshree Mishra

Jayshree Mishra
Jayshree Mishra, PhD

Research Associate Professor of Pharmaceutical Sciences

Contact

Texas A&M Irma Lerma Rangel School of Pharmacy
1010 W. Ave. B
Kingsville, TX 78363
jayshree.mishra@tamu.edu
Phone: 361.221.0963
Fax: 361.221.0798

Education and Training

  • Irma Lerma Rangel School of Pharmacy, Research Assistant Professor
  • Irma Lerma Rangel School of Pharmacy, Research Scientist
  • Indian Institute of Technology, Kharagpur India, PhD, Microbial Biotechnology
  • Indian Institute of Technology, Kharagpur India, Master’s in technology, Applied Botany
  • Texas A&M university-Health science Center and Texas A&M University Kingsville, Graduate Faculty Member

Research Interests

  • Role of drug transporter proteins in colonic mucosal innate immunity
  • Development of novel therapeutics for metastatic- triple negative breast cancer

Teaching Interests

  • Clinical Biochemistry
  • Pharmacology (Targeted Therapies)- Oncology, transplant, and Genomics
  • Cardiovascular Pharmacology
  • Biotech products and Vaccine development
  • Immunology

Awards, Recognition and Service

  • National Institutes of Health-Small Business Innovation Research (SBIR/STTR) award (Role: Co-Principal Investigator on University sub-contract)
  • NIH Adhoc grant reviewer June 2022 (NIH study section- Cellular and Molecular Immunology; CIMA)
  • Walk Across the Texas Championship award, 2018 & 2022
  • Awards from Discovery Foundation towards Women’s Health 2021
  • Texas A&M Health Science Center 5 years of outstanding service award
  • Texas A&M University-Program to Enhance Scholarly and Creative Activities Award-2018
  • American Society of Investigative Pathology- Program Committee member
  • Annual American Society of Investigative Pathology meeting – Session Chair Inter-Organ Communication in Tissue Homeostasis and Pathology session”
  • NIH/ NIGMS/ American Society of Microbiology ABCRM Faculty judge Award (From 2016-2021)
  • Travel Award; Gordon Research Conference
  • Travel Award: Academic Skill Workshop organized by AGA Institute and AASLD Institute
  • Second Best Poster presenter award 1st Annual Research Colloquium-2010
  • GI Investigator Development Research Award from ACCP Research Institute
  • "Laboratory Mentor Award” for Upward Bound Math & Science program from Texas A&M University-Kingsville
  • “Certificate of Recognition for chairing the session” in Pharmacovigillence-2013.”
  • Awarding agency: OMICS Publishing Group
  • Organizing committee member of International Conferences *Pharmacovigillence-2013, San Antonio, Texas; *Pharmacovigillence-2014, Hyderabad, India; *World Nutraceutical Conference and Expo-2015, Philadelphia, Penn.
  • DAAD Fellowship; Government of Federal Republic of Germany; Graduate scholarship to do advance research on hydrogen Biotechnology at Ruhr University, Bochum, Germany
  • Jawaharlal Nehru Memorial Fund Award; Government of India, Delhi; Type: Ph.D. scholarship to continue research in India
  • Graduate Aptitude Test in Engineering Scholarship Awarding agency: Department of Biotechnology, Government of India Type: To pursue Master of Technology in Indian Institute of Technology, India (1998-2001)
  • NOVEL GENE CLONED; Accession #: AY676139 [gi: 62914769] in NCBI Gene Bank]. National Center for Biotechnology Information

Patents

  • Kumar N, and Mishra J. Methods of Screening for Janus Kinase 3 Interacting Compounds. United States Patent. Patent No.: US 9,739,779. Date of award: Aug 22, 2017
  • Kumar N, and Mishra J. A Novel High Throughput Assay for finding new Jak3 Interacting Compounds, Biomolecules, and Inhibitors. US Non-Provisional patent number US 14/483,622; US20150344934 A1. (Under negotiation for licensing)
  • Kumar N, and Mishra J. Biomarkers for Early Detection of Colorectal Cancer. TAMU-HSC. No.: 4812HSC18. Date: September 11, 2017
  • Jayshree Mishra and Narendra Kumar Jak3-SH2 domain targeted new class drugs for Triple negative breast cancer-brain metastasis (Disclosure Filed in 2023)
  • Jayshree Mishra and Narendra Kumar Artificial intelligence based new class of Jak3-targeted drugs for Triple negative breast cancer metastasis (Disclosure filed in 2023)
  • Narendra Kumar and Jayshree Mishra Sweat test based non-invasive diagnosis for lung cancer. (Disclosure Filed in 2023)
  • Narendra Kumar and Jayshree Mishra Smart drug for lung cancer (Disclosure Filed in 2023)
  • Narendra Kumar and Jayshree Mishra Jak3-SH2 domain targeted a new class drug for metastatic lung cancer. (Disclosure Filed in 2023)

Representative Publications

Kumar N, Segovia D, Kumar P, Atti HB, Kumar S, Mishra J. Mucosal implications of oral Jak3-targeted drugs in COVID patients. Molecular Medicine Mol Med. 2025;31(1):203. doi:10.1186/s10020-025-01260-z.

Momen YS, Mishra J, Kumar N. Brain-Gut and Microbiota-Gut-Brain Communication in Type-2 Diabetes Linked Alzheimer's Disease. MDPI Nutrients. 2024;16(15):2558. doi:10.3390/nu16152558.

Tihong Shao, Ronald Hsu, Desiree L. Rafizadeh, Li Wang, Christopher L. Bowlus, Narendra Kumar, Jayshree Mishra, Suraj Timilsina, William M. Ridgway, M. Eric Gershwin, Aftab A. Ansari, Zongwen Shuai, Patrick S.C. Leung. The Gut Ecosystem and Immune Tolerance. Elsevier Journal of Autoimmunity. In press, 2023. Impact Factor: 14.5.

Mishra J, Stubbs M, Kuang L, Vara N, Kumar P, Kumar N. Inflammatory Bowel Disease Therapeutics: A Focus on Probiotic Engineering. Hindawi Publishing Corporation Mediators Inflamm. 2022;2022:9621668. doi:10.1155/2022/9621668.

Narendra Kumar, Salim Surani, George Udeani, Sara Mathew, Sharon John, Soniya Sajan, Jayshree Mishra. Drug-induced liver injury and prospect of cytokine therapy: A focus on IL-2 based therapies. Elsevier Life Sciences. 2021;278:119544.

Narendra Kumar, Longxiang Kuang, Ryan Villa, Priyam Kumar, Jayshree Mishra. Mucosal epithelial Jak kinases in health and diseases. Hindawi Publishing Corporation Mediators of Inflammation. 2021;2021:6618924.

Jayshree Mishra and Narendra Kumar. Intestinal (BCRP) for drug efflux and barrier functions in obesity. Medicine Innovates. 2020; Mechanism of Action volume.

Jayshree Mishra and Narendra Kumar. Intestinal Breast Cancer Resistance Protein (BCRP) requires Janus Kinase 3 activity for drug efflux and barrier functions in obesity. American Society for Biochemistry and Molecular Biology J Biol Chem. 2019;294(48):18337–18348.

Jayshree Mishra, Jugal Kishore Das, and Narendra Kumar. Janus Kinase 3 phosphorylation of β-catenin NTD regulates adherence junction. American Society for Biochemistry and Molecular Biology J Biol Chem. 2017;292(40):16406–16419. PMID: 28821617.

Jayshree Mishra, Raj K. Verma, and Narendra Kumar. Role of Janus Kinase 3 in predisposition to obesity and metabolic syndrome. American Society for Biochemistry and Molecular Biology J Biol Chem. 2015;289(23):15951–15956.

Jayshree Mishra and N. Kumar. Adapter protein Shc regulates Janus kinase 3 phosphorylation. American Society for Biochemistry and Molecular Biology J Biol Chem. 2014;289(23):15951–15956.

Jayshree Mishra, C. Waters, N. Kumar. Molecular mechanism of interleukin-2 induced mucosal homeostasis. American Physiological Society Am J Physiol Cell Physiol. 2012;302(5):C735–C747.

Kumar, Jayshree Mishra, Sohel Quazi. Training the defense system for modern-day warfare: the horizons for immune-related cancer treatment and vaccines for cancer. J Immunodefic Disord. 2012;1(2):e106.

Jayshree Mishra, J. Dromund, S.H. Quazi, S.S. Karanki, J.J. Shaw, B. Chen, N. Kumar. Prospective of colon cancer treatments and scope for combinatorial approach for enhanced cancer cell apoptosis. Elsevier Crit Rev Oncol Hematol. 2012.

Jayshree Mishra, Karanki S. Kumar N. Identification of molecular switch regulating interaction of Janus Kinase 3 with cytoskeletal proteins. American Society for Biochemistry and Molecular Biology J Biol Chem. 2012;287(49):41386–41391.

Jayshree Mishra, Z.Q., B. Neudeck. Activation of TLR-4 receptor increases cell surface P-glycoprotein expression with decreased activity. American Society for Pharmacology and Experimental Therapeutics Drug Metabolism and Disposition. 2008;36(10):2145–2149.

Kumar, Jayshree Mishra, V.S. Narang, C.M. Waters. Janus Kinase 3 (Jak3) regulates interleukin-induced mucosal wound repair through tyrosine phosphorylation of villin. American Society for Biochemistry and Molecular Biology J Biol Chem. 2007;282(42):30341–30345.

Spotlight

Research Funding & Grant Support

  • NIH-SBIR-GM109528 (Co-Investigator: Mishra)
    Development of a Novel ELISA Kit for Screening Potential JAK3 Inhibitors
    06/2014 – 06/2016
  • Vishal Raju Bhagat Foundation Grant (PI: Mishra)
    Development of an Oral Microbiome-Based Novel Biomarker for the Early Detection of Childhood Obesity
    07/2018 – 12/2020
  • Texas A&M University-PESCA Grant (PI: Mishra)
    Development of a Novel Biomarker for the Early Detection of Colon Cancer
    06/2019 – 07/2022
  • Discovery Foundation Grant (PI: Mishra)
    Discovering a Novel Class of JAK3-Directed Chemotherapeutic Agents for the Treatment of Metastatic Triple-Negative Breast Cancer
    /01/01/2022 – 01//01/ 2024
  • Texas A&M Research and Innovation – Advancing Discovery to Market Award Type I (PI: Mishra)
    Discovering a Novel Targeted Therapeutic to Treat Triple-Negative Breast Cancer Metastasis
    09/01/2023 – 09/01/2025
  • Texas A&M Research Leadership Fellowships (RLF) (Co-Investigator: Mishra; Multidisciplinary Team)
    Role of Gut microbial Metabolites in Cardiovascular Complications
    06/01/2023 – 10/01/2024
  • Texas A&M Research and Innovation – High Impact Seedling Grant (PI: Mishra)
    Characterization of TYK2 as a Novel Therapeutic Target and Development of a TYK2-Targeted Drug for Triple-Negative Breast Cancer Brain Metastasis
    06/01/2024 – 10/01/2025
  • Texas A&M Research and Innovation – Commercialization Gap Funding (PI: Mishra)
    Development of a non -kinase domain targeted of Targeted Therapeutics for Triple Negative Breast Cancer-Brain metastasis​09/01/2023 – 09/01/2025
  • Texas A&M Research and Innovation – Commercialization Gap Funding (Co-Investigator: Mishra)
    Tyk-2 As Novel Therapeutic Target & Concomitant Develop a Of A Tyk2 targeted compound to treat Metastatic Triple Negative Breast Cancer 09/01/2023 – 09/01/2025
  • Texas A&M Research and Innovation – High Impact Seedling Grant (Co-Investigator: Mishra)
    09/01/2023 – 09/01/2025
  • Texas A&M University TPT Seed Grant (PI: Mishra; Multidisciplinary Team)
    Mechanistic Basis and Therapeutic Exploitation of Metabolic Reprogramming in Triple-Negative Breast Cancer Brain Metastases " 04/01/2026 – 03/31/2027
  • Texas A&M Research and Innovation – Advancing Discovery to Market Award Type II (PI: Mishra)
    Development of a First-in-Class Jak3-Targeted Therapy for TNBC Brain Metastases: Efficacy, Pharmacodynamics, and Translational Pharmacokinetics 06/01/2026 – 06/01/2027

Lab Members

Mimansha Saha: Research Associate

Sarah J Harder-Neely: Former student research Assistant